Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

Delayed Quote. Delayed  - 08/30 05:30:38 pm
78.1 CHF   +0.32%
08/30 AMGEN : Novartis wins US OK for biosimilar version of Amgen's Enbrel
08/30DJFDA Approves Novartis's Biosimilar to Amgen's Enbrel
08/30DJNOVARTIS : FDA Approves Novartis's Biosimilar to Amgen's Enbrel
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Amgen : Novartis wins US OK for biosimilar version of Amgen's Enbrel

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/30/2016 | 11:21pm CEST

U.S. regulators on Tuesday approved the first lower-cost version of Enbrel, a blockbuster anti-inflammatory drug from Amgen that is among the top-selling drugs in the world.

The Food and Drug Administration cleared the near-copy of the drug, dubbed Erelzi, developed by Swiss drug giant Novartis, which would not disclose the planned list price for the drug.

A month's supply of Enbrel costs roughly $4,000 or more in the U.S., according to figures from GoodRx, a drug pricing website. Enbrel was the fourth best-selling prescription drug in the world for 2015, according to health data firm IMS Health.

The FDA approved Novartis' drug for the same diseases listed on Enbrel's label, including rheumatoid arthritis, psoriasis and other immune system disorders.

The announcement marks the third FDA approval of a so-called biosimilar drug, the industry term for generic biotech medicines, used to indicate they are not exact copies of the original products. Already available in Europe, the drugs have the potential to generate billions in savings for insurers, doctors and patients.

But savings from Enbrel could be delayed for years due to an ongoing legal dispute over the drug, according to analyst reports.

Under a court order dated Aug. 11, Amgen Inc. and Sandoz, a unit of Novartis, agreed to a preliminary injunction blocking the launch of Erelzi. Both companies refused to discuss how long that injunction will last.

Morgan Stanley analyst Matthew Harrison said the agreement indicates that a trial would not begin until April 2018. Under that timeline, a near-term launch of lower-cost Enbrel "is off the table," he states in a recent note to investors.

Erelzi is Novartis' second competitor to an Amgen drug. Last March Novartis won approval for a biosimilar version of Amgen's drug Neupogen — the first biosimilar approved in the U.S. Pfizer won approval to market a second biosimilar in April, a version of Johnson & Johnson's Remicade.

Enbrel was Amgen's top-selling drug last year with $5.1 billion in U.S. sales and $5.4 billion worldwide. The injectable medicine was first approved in 1998, part of a class of multi-billion dollar drugs that reduce inflammation and help control the immune system. The class also includes Remicade and AbbVie's Humira, which is also facing potential competition from biologic versions in development.

Biotech drugs are powerful, injected medicines produced in living cells that are typically much more expensive than traditional, chemical-based drugs. In 2015, six of the 10 top-selling medicines globally were biotech drugs, with more than $56 billion in combined sales.

Copyright 2016 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed., source Associated Press News

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS AG
08/30 AMGEN : Novartis wins US OK for biosimilar version of Amgen's Enbrel
08/30DJFDA Approves Novartis's Biosimilar to Amgen's Enbrel
08/30DJNOVARTIS : FDA Approves Novartis's Biosimilar to Amgen's Enbrel
08/30 NOVARTIS : FDA approves Sandoz Erelzi(TM) to treat multiple inflammatory disease..
08/30 CONTRACT AWARD - J-- GOVERNMWNT OWNE : Pmi constellation: 9/1/16-8/31/17
08/30 NOVARTIS : $12,482 Federal Contract Awarded to Alcon Laboratories
08/30 NOVARTIS AG (ADR) (NYSE : NVS) Says A Picture Is Worth A Thousand Words
08/29 GLAXOSMITHKLINE : Ahmed - GSK Has Full Confidence in the Nigerian Economy
08/29 AHMED : GSK Has Full Confidence in the Nigerian Economy
08/29 NOVARTIS : convenes experts to discuss new technologies in healthcare at Interna..
More news
Sector news : Pharmaceuticals - NEC
02:55aDJWALGREENS BOOTS ALLIANCE : Theranos Walks Away From Zika Test
01:33a ASTRAZENECA : to pay $5.52 million to resolve U.S. SEC foreign bribery case
08/30 U.S. slams EU, but Apple tax demand first issued in Washington
08/30DJFDA Approves Novartis's Biosimilar to Amgen's Enbrel
08/30DJFertilizer Producers Agrium and Potash in Merger Talks
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
08/30 FDA OKs Novartis' Enbrel biosimilar
08/30 Parsabiv NDA Fails; Implications For Amgen
08/29 CTI Bio's late-stage study of lead product candidate pacritinib shows mixed r..
08/28 Momenta Has Momentum After Recent Patent Decision
08/25 Siponimod Rides To Novartis' Rescue
Advertisement
Financials ($)
Sales 2016 48 839 M
EBIT 2016 11 354 M
Net income 2016 7 849 M
Debt 2016 14 751 M
Yield 2016 3,56%
P/E ratio 2016 23,54
P/E ratio 2017 21,17
EV / Sales 2016 4,58x
EV / Sales 2017 4,45x
Capitalization 208 887 M
More Financials
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 89,5 $
Spread / Average Target 12%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG-10.83%208 887
JOHNSON & JOHNSON16.74%328 086
PFIZER INC.8.77%212 965
ROCHE HOLDING LTD.-12.84%212 954
MERCK & CO., INC.19.29%174 236
ASTRAZENECA PLC7.33%173 471
More Results